Ambulatório/Laboratório de Hepatites Virais, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Laboratório de Desenvolvimento Tecnológico em Virologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Biomed Res Int. 2018 Jan 9;2018:5769201. doi: 10.1155/2018/5769201. eCollection 2018.
Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immunocompromised individuals. Ribavirin has been shown to be effective as a monotherapy to induce HEV clearance in chronic patients who have undergone solid organ transplant (SOT) under immunosuppressive therapy. Efforts and improvements in prevention and control have been made to reduce the instances of acute and chronic hepatitis E in endemic and nonendemic countries. However, this review shows that further studies are required to demonstrate the importance of preventive vaccination and treatment worldwide, with emphasis on hepatitis E infection in the public health system.
戊型肝炎病毒 (HEV) 是全球范围内常见的急性病毒性肝炎病因。已开发出重组 HEV 疫苗，但自 2011 年以来，只有一种在中国获得商业许可。流行病学研究表明，基因型 3 是免疫功能低下个体慢性感染的主要原因。利巴韦林已被证明可有效作为单药治疗，诱导接受免疫抑制治疗的实体器官移植 (SOT) 后的慢性患者清除 HEV。已经做出努力并改进了预防和控制措施，以减少地方性和非地方性国家中急性和慢性戊型肝炎的发生。然而，本综述表明，需要进一步的研究来证明全球范围内预防性疫苗接种和治疗的重要性，重点是公共卫生系统中的戊型肝炎感染。
Zotero 插件